Overview

Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

Status:
Completed

Trial end date:
2018-10-12

Target enrollment:
0

Participant gender:
All

Summary

To Evaluate the Efficacy and Safety of CKD-495

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Treatments:

Ethanol
Rebamipide

Criteria

Inclusion Criteria:

1. Male or Female subjects aged ≥ 19

2. Acute or Chronic gastritis patients who have more than 1 erosion on endoscopy within
7days prior to the use of the Investigator's Product taken date

3. Patients who have more than 1 subjective symptom

Exclusion Criteria:

1. Patients with peptic ulcer, gastroesophageal reflux disease, malignant tumor in the
digestive system or coagulation disorder, or taking antithrombotic medicine

2. Patients who have been taken any gastritis medicine that could affect the treatment:
H2 receptor antagonist, PPI(Proton Pump Inhibitor), antacid, improvement of movement
in digestive system, Prostaglandin, and protective agent for gastritis

3. Patients who have to take medicine that could cause gastritis